tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Prelude Therapeutics reports Q2 EPS (41c), consensus (43c)
PremiumThe FlyPrelude Therapeutics reports Q2 EPS (41c), consensus (43c)
2M ago
PRLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
PRLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study
Premium
Company Announcements
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study
2M ago
Prelude Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsPrelude Therapeutics Reports Q1 2025 Financial Results
5M ago
Prelude Therapeutics Reports Strong Q1 2025 Financial Results
Premium
Company Announcements
Prelude Therapeutics Reports Strong Q1 2025 Financial Results
5M ago
Prelude Therapeutics’ PRT3789 Shows Promising Selectivity in SMARCA2 Degradation, Justifying Buy Rating
Premium
Ratings
Prelude Therapeutics’ PRT3789 Shows Promising Selectivity in SMARCA2 Degradation, Justifying Buy Rating
5M ago
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
PremiumThe FlyPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
7M ago
Prelude Therapeutics sees cash runway into 2Q26
Premium
The Fly
Prelude Therapeutics sees cash runway into 2Q26
7M ago
PRLD Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
PRLD Earnings this Week: How Will it Perform?
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100